SIOX Sio Gene Therapies Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

ESG framework	Mentions in filings
Sustainability Accounting Standards Board (SASB)	❌
Global Reporting Initiative (GRI)	❌
Task Force on Climate-related Financial Disclosures (TCFD)	❌
UN Sustainable Development Goals (SDGs)	❌

ESG term mentions

In last year of SEC filings

Contaminant Emission Environment Environmental Environmental Protection Forest Intensity Life Cycle Materials Nature Offset Package Packaging Pandemic Raw Materials Regenerative Toxic Waste Wind Access Attrition Benefits Black California Consumer Privacy Act Collective Bargaining Community Customer Cyber Cybersecurity Data Privacy Death Disability Diversity Drug Pricing Employee Engagement Health and Safety Health Care Healthcare Hire Hiring Human Resources Incident Injury Minority Privacy Product Quality Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Society Supplier Supply Chain Talent Training Union Volunteer Workers Workforce Working Condition Action Plan Anti-corruption Antitrust Assessment Assurance Attorneys General Audit Bonus Bribery Chronic Class Action Lawsuit Classified Commitment Conflict of Interest Corporate Governance Corruption Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigant Litigation Long-term Majority Mission Oversee Oversight Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Self-evaluation Shareholder Proposals Special Meeting Strategy Supermajority Sustainable Targets Tax Transparency Transparent

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On September 24, 2020, Axovant Gene Therapies Ltd. (the “Company”) held its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders considered and approved two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 12, 2020.

Of the 41,797,294 common shares outstanding as of the record date, 37,014,259 shares, or 88.6%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of shareholders at the Annual Meeting.

Proposal No. 1: The following six nominees for director were elected to serve as directors of the Company until the Company’s 2021 Annual General Meeting of Shareholders and until their successors are duly elected, by the following votes:

Name	Votes For	Votes Against	Abstain	Broker Non-Votes

Frank Torti, M.D.	17,715,500	2,472,995	22,663	16,803,101
Atul Pande, M.D.	19,857,330	329,778	24,050	16,803,101
Pavan Cheruvu, M.D.	17,710,786	2,475,333	25,039	16,803,101
Berndt Modig	19,906,804	276,494	27,860	16,803,101
Senthil Sundaram	19,847,132	331,586	32,440	16,803,101
Eric Venker, M.D., Pharm.D.	17,741,465	2,441,958	27,735	16,803,101

Proposal No. 2: The shareholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending March 31, 2021 and the appointment of Ernst & Young LLP as the Company’s auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for its fiscal year ending March 31, 2021, and authorized the Company’s Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as the Company’s auditor for its fiscal year ending March 31, 2021, by the following votes:


Votes For	Votes Against	Abstain
36,771,288	163,819	79,152